Compared to non-NAFLD of HCC patients with cirrhosis, GNG4, EPCAM, SPARCL1, DGKK, and SLC39A4 were down-regulated and HOXD9 was up-regulated in NAFLD of HCC patients with cirrhosis. Here, EPCAM is linked to metabolic dysfunction-associated steatotic liver disease.